{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:16:30Z","timestamp":1793412990973,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vision"],"abstract":"<jats:p>This pharmacovigilance study drew upon the U.S. Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database to compare the reporting patterns of ocular and systemic adverse events (AEs) for the 2 mg (standard-dose [SD]) and 8 mg (high-dose [HD]) formulations of aflibercept given for any ocular indication. Disproportionality analysis, including reporting odds ratios (ROR), was used to compare each dose individually to the background reporting rate for the AE. Statistical significance of the RORs was evaluated using Bonferroni correction, alongside signal detection based on Evans criteria, and Bayesian information components. The Breslow\u2013Day test was used to conduct a head-to-head comparison of RORs between each dose. We identified 953 SD and 314 HD AE reports within the 750-day period after the approval of HD by the U.S. Food and Drug Administration (FDA; 8\/18\/2023). Compared to SD, HD had a higher ROR for endophthalmitis (HD: ROR 767.56 [95% CI, 466.11\u20131263.95]; SD: ROR 331.64 [95% CI, 216.71\u2013507.51]), eye inflammation (HD: ROR 118.45 [95% CI, 55.85\u2013251.20]; SD: 43.98 [95% CI, 21.87\u201388.44]), retinal vasculitis (HD: ROR 769.87 [95% CI, 337.13\u20131758.04]; SD: ROR 124.80 [95% CI, 39.67\u2013392.63]), and systemic vasculitis (HD: ROR 28.40 [95% CI, 14.63\u201355.14]; SD: ROR 4.05 [1.52\u201310.82]). These results, based on FAERS, indicate associations rather than causal relationships. Further studies are needed to quantify the absolute risks and elucidate the mechanisms underlying differences in safety signals, if any.<\/jats:p>","DOI":"10.3390\/vision10020018","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:09:18Z","timestamp":1774944558000},"page":"18","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse Events Reported with Standard-Dose and High-Dose Aflibercept: A FAERS Pharmacovigilance Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-1903","authenticated-orcid":false,"given":"Minali","family":"Prasad","sequence":"first","affiliation":[{"name":"Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA"},{"name":"Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-812X","authenticated-orcid":false,"given":"David J.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA"},{"name":"Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA"},{"name":"Department of Biomedical Sciences and Disease, New England College of Optometry, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"The CATT Research Group (2011). Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 364, 1897\u20131908.","DOI":"10.1056\/NEJMoa1102673"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: Systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_7","unstructured":"Food and Drug Administration (2025, September 05). Eylea (Aflibercept), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2011\/125387s000ltr.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","article-title":"Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","article-title":"Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab","volume":"135","author":"Bressler","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamaophthalmol.2015.1880","article-title":"Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network","volume":"133","author":"Jampol","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jamaophthalmol.2016.3698","article-title":"Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial","volume":"134","author":"Jampol","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamaophthalmol.2015.4599","article-title":"Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","volume":"134","author":"Wells","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_19","unstructured":"Center for Drug Evaluation and Research (2025, September 05). 761355Orig1s000 Summary Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761355Orig1s000SumR.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"RLanzetta","year":"2024","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"ref_22","unstructured":"Bayer, P. (2023). A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection into the Eye Works and How Safe It Is in People with Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e002091","DOI":"10.1136\/bmjophth-2024-002091","article-title":"Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: A case series","volume":"10","author":"Sambhara","year":"2025","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/life15060903","article-title":"Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom","volume":"15","author":"Musadiq","year":"2025","journal-title":"Life"},{"key":"ref_25","unstructured":"(2025, September 05). FDA\u2019s Adverse Event Reporting System (FAERS). U.S. Food & Drug, Available online: https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers."},{"key":"ref_26","unstructured":"(2025, September 05). OpenFda. U.S. Food & Drug Administration, Available online: https:\/\/open.fda.gov\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_28","unstructured":"(2025, September 05). FAERS Quarterly Data Files Documentation. U.S. Food & Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/faers-quarterly-data-files-documentation."},{"key":"ref_29","unstructured":"Center for Drug Evaluation and Research (2025, September 05). 125387Orig1s060. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/125387Orig1s060.pdf?."},{"key":"ref_30","unstructured":"Python Software Foundation (2025, September 05). Python Language Reference, Version 3.13.7. Available online: https:\/\/www.python.org."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.oret.2025.08.018","article-title":"Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis","volume":"10","author":"Lakhani","year":"2025","journal-title":"Ophthalmol. Retin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lakhani, M., Popovic, M.M., Al-Ani, A., Kundapur, D., Gholamian, T., Chaudry, E., Nanji, K., Patil, N., Feo, A., and Sadda, S. (2025). Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries. Ophthalmol. Retin., in press.","DOI":"10.1016\/j.oret.2025.10.019"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40261-017-0574-4","article-title":"Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"37","author":"Rahman","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/OPTH.S409103","article-title":"Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway","volume":"17","author":"Reitan","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e001188","DOI":"10.1136\/bmjophth-2022-001188","article-title":"Quantifying burden of intravitreal injections: Questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII)","volume":"7","author":"Wang","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.2147\/OPTH.S533237","article-title":"Caregiver Burden Among Patients Receiving Anti-VEGF Intravitreal Injections for AMD and DR: A Cross-Sectional Study in Guangzhou","volume":"19","author":"Lin","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100202","DOI":"10.1016\/j.xops.2022.100202","article-title":"Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation","volume":"2","author":"Raevis","year":"2022","journal-title":"Ophthalmol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ophtha.2023.12.033","article-title":"Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections","volume":"131","author":"Israilevich","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/24741264211028519","article-title":"Board Certification Is Associated With a Reduced Risk of Endophthalmitis After Intravitreal Injections","volume":"6","author":"Emerson","year":"2022","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: A systematic review and meta-analysis","volume":"12","author":"Shahzad","year":"2023","journal-title":"Syst. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41433-024-03370-0","article-title":"Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration","volume":"39","author":"Teo","year":"2025","journal-title":"Eye"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Alali, N.M., Aljahdali, A., AlBalawi, H.B., Al Jarallah, O.J., Al Zaid, S.M., Abuallut, I., Almarek, F., Shajry, I., Alotaibi, Y.A., and Hazzazi, M.A. (2025). Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111620"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hoffmann, L., Michels, S., Eandi, C., Karam, M.A., Figueiredo, E.C.d.O., and Hatz, K. (2024). Aflibercept high-dose (8mg) related intraocular inflammation (IOI)\u2014A case series. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03788-w"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: A narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","article-title":"Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction","volume":"3","author":"Koren","year":"2002","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_48","unstructured":"Regeneron Pharmaceuticals, Inc. (2025, September 05). Eylea (Aflibercept) Injection: Highlights of Prescribing Information [Package Insert]. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125387s087lbl.pdf."},{"key":"ref_49","unstructured":"Regeneron Pharmaceuticals, Inc. (2025, September 05). Eylea HD (Aflibercept) Injection: Highlights of Prescribing Information [Package Insert]. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761355s000lbl.pdf."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Burridge, S., Stratton, R., and Asaria, R. (2021). Systemic Inflammatory Reaction to Intravitreal Bevacizumab: A Case Report. Res. Sq. .","DOI":"10.21203\/rs.3.rs-422581\/v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00417-021-05353-3","article-title":"Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors","volume":"260","author":"Moret","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ICB.0000000000000581","article-title":"Allergic reaction upon intravitreal administration of anti-vascular endothelial growth factor agents","volume":"13","author":"Meredith","year":"2019","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.21037\/acr-23-107","article-title":"Severe Guillain-Barre syndrome induced by intravitreal injection of ranibizumab for branch retinal vein occlusion: A case report","volume":"8","author":"Zhou","year":"2024","journal-title":"AME Case Rep."},{"key":"ref_54","unstructured":"Centers for Medicare & Medicaid Services (2025, September 05). The 2024 Part B National Summary Data File, Available online: https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/part-b-national-summary-data-file."},{"key":"ref_55","first-page":"2398","article-title":"Early insights on the real-world use of aflibercept 8 mg among treatment-naive eyes with diabetic macular edema","volume":"66","author":"Mehta","year":"2025","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_56","unstructured":"Regeneron Pharmaceuticals, Inc. (2025, September 05). Eylea HD (Aflibercept) Injection: Highlights of Prescribing Information [Package Insert]. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761355s010lbl.pdf."},{"key":"ref_57","unstructured":"FDA (2025, September 05). FDA Adverse Event Reporting System (FAERS) Public Dashboard, Available online: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."}],"container-title":["Vision"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2411-5150\/10\/2\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T01:37:58Z","timestamp":1775439478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2411-5150\/10\/2\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vision10020018"],"URL":"https:\/\/doi.org\/10.3390\/vision10020018","relation":{},"ISSN":["2411-5150"],"issn-type":[{"value":"2411-5150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}